# Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

> **NCT00110396** · PHASE3 · COMPLETED · sponsor: **EMD Serono** · enrollment: 260 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Interferon-beta-1a FBS-free/HSA-free

## Key facts

- **NCT ID:** NCT00110396
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2015-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110396, "Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00110396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*